Preparation and Characterization of Solid Lipid Nanoparticles Loaded with Cisplatin
Abstract
Cisplatin (Cis diaminedichloro platinum) was the first platinum drug to be used as an anticancer drug, and it is widely used in the treatment of testicular, head, neck, ovarian and lung cancer. The use of Cisplatin is limited due to its intrinsic and acquired resistance and severe side effects such as chronic neurotoxicity and nephrotoxicity. The colloidal carriers such as emulsion, liposomes, polymeric nanoparticles have been extensively studied to overcome above limitations. The solid lipid nanoparticles (SLNs), amongst other colloidal carriers, were found to be an ideal carrier for lipophillic drug for better stability and release retardation. Cisplatin loaded solid lipid nanoparticles was prepared by microemulsion technique. Stearic acid was used as lipid. The other excipients were used as DPPG, Soya lecithin and Poloxamer P407 and acidic buffer PH4. Also used Probe sonication for 10 min at 79 Amplitude. Cisplatin SLNs Batch C13 showed particle size of 119.23±1.52 nm, Zeta potential of -37.33±2.47 mV, % Entrapment efficiency of 90.2 ± 2.1 %., % Drug loading capacity of 1.62 ± 1.34 %., The TEM study of optimized Cisplatin SLN illustrated the spherical shape of nanoparticles. Total release amount of Cisplatin was 82.62± 2.04 % after 48 hrs. The formulation performed kinetics study followed Peppas plot equation The SLNs of Cisplatin met all the requirements of a colloidal drug delivery system. They had particle size in nanosize; their size distribution was narrow and all the particles were in spherical shape and stable.
Keywords: Cisplatin, Solid Lipid nanoparticles, zeta potential, Particle size, Transmission electron Microscopy.
DOI
https://doi.org/10.22270/jddt.v8i6.2033References
2. Mukherjee S, Roy S, Thakur RS, Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System, Indian Journal of Pharmaceutical Sciences, 2009; 71(4):349-358.
3. Reddy R.N., Sharif A, Solid Lipid Nanoparticles: An Advanced Drug Delivery system, 2013; 4(1):161-171.
4. Sathali AH, Ekambaram P, Priyanka K. Solid Lipid Nanoparticles: A Review. Scientific Reviews and Chemical. Communication2012; 2(1):80-102.
5. Doijad RC, Manvi FV, Ghodhwani DM, Joseph R, Deshmukh NV, Formulation and Targetting efficiency of cisplatin Engineered solid lipid nanoparticles, Indian journal of pharmaceutical sciences, 2008; 203-207.
6. Bende Kruijff, Gea Speelmans, Wendy H.H.M. Sips, Ruud J. H. Grisel, Rutger,. M. Staffhorst, Anne Marie J. Fichtinger-Schepman, Jan Reedijk, The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and takes place at low chloride ion concentration , Biochimica et Biophysica Acta(BBA)-Biomembranes,1996; 1284(1):60-66.
7. Pandita D, Ahuja A, Velpandian T, Lather V, Dutta T, Khar RK, Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique, Pharmazie, 2009; 64: 5
8. Singh S, Dobhal AK, Jain A, Pandit JK, Formulation and Evaluation of Solid Lipid Nanoparticles of a water soluble drug: Zidovudine, Chem. Pharm, Bulletin, 2010; 58/(5):650-655.
9. DaWei C, Yi Fan L, LiXiang R, XiuLi Z, Solid lipid nanoparticles for enhancing Vinpocetine’s oral bioavailability, Journal of controlled release, 2006; 114:53-59.
10. Deshmukh NV, Doijad RC, Bhambere DS, Somapur C And Goje A, Patel KS. Colloidal drug delivery of biodegradable poly (lactide-coglycolide) (plg) injectable nanoparticles for anticancer Drug, international journal of drug development & research;2010; 2(4):681
Published
Abstract Display: 1451
PDF Downloads: 1206 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

.